Company Overview and News
The roaring run of bulls continued at Dalal Street as equity benchmarks ended at fresh record closing highs on Friday despite tepid global cues. Technology, pharma, metals and select FMCG stocks also participated in the rally. (43-0)
Sun Pharmaceutical Industries, India’s largest drug maker, on Tuesday said it has reached an agreement with US-based Ironwood Pharmaceuticals and Allergan Plc to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Linzess capsules in the US. (70-0)
Pharma stocks cooled-off in second week of January, after starting the year on strong note. The overall bullish sentiment of the stock markets didn't rub on to the pharma stocks. (2-0)
At least four Indian drug makers including Aurobindo Pharma, Cadila Healthcare, Torrent Pharma and Intas are said to be eyeing the generic business put on block by French pharmaceutical group Sanofi, according to a report in Economic Times. (2-0)
On Wednesday Alok Sonig, vice-president (Global), Dr Reddy’s Laboratories, will be presenting his company’s strategy for limited-competition products at the ongoing JP Morgan Healthcare Conference in San Francisco. Sonig is not alone.
Mumbai: Aurobindo Pharma Ltd is strengthening its product pipeline and plans to have a diversified portfolio, including cancer drugs, complex injectables, respiratory products, peptides, topicals and transdermals, and biosimilars, which will drive growth in the coming years.
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
New Delhi: The Indian rupee on Wednesday slipped in early trade and opened lower by 7 paise at Rs. 63.55 per dollar versus Rs. 63.48 on Tuesday, where the local currency was up by 0.31 percent from its previous closing. The rupee on Tuesday had also hit its highest level against the dollar in about two and-a-half years amidst signs of weakness in the US currency. (10-0)
New Delhi: The Indian rupee on Wednesday slipped in early trade and opened lower by 7 paise at Rs. 63.55 per dollar versus Rs. 63.48 on Tuesday, where the local currency was up by 0.31 percent from its previous closing.
9:33 am RIL gains: Investors in shares of Reliance Industries cheered the commissioning of the world’s largest refinery off-gas cracker complex at Jamnagar. The stock was higher by around 2 percent intraday (12-0)
The Indian benchmark indices on the first day of the new year were trading flat with the Sensex adding 12 points and was trading at 34068 while the Nifty was flat at 10530. (7-0)
10:05 am FII View: Indranil Sen Gupta of Bank of America Merrill Lynch said the government's decision to borrow another Rs 50,000 crore was an avoidable negative surprise in an already nervous G-Sec market. (23-0)
Mumbai: NSE benchmark Nifty saw some correction towards the fag-end of today’s trade to slip by 41 points following selling pressure mainly in energy, infra, realty and banking sectors. (14-0)
The market corrected in last hour of trade on Wednesday after hitting fresh record highs intraday, weighed by concerns of rising crude oil prices and likely increase in government borrowing. Investors also remained cautious ahead of last expiry of the year. (18-0)
Aurobindo Pharma shares gained 2.5 percent intraday Wednesday after receiving approval from the US health regulator for Fondaparinux Sodium injection.
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton